Abstract: A disclosed methodology for syndrome extraction in a quantum measurement circuit includes generating a graph representing a code implemented by the quantum measurement circuit. The graph includes bit nodes corresponding to data qubits in the quantum measurement circuit, check nodes corresponding to syndrome qubits in the quantum measurement circuit, and edges between the bit nodes and check nodes that are each associated with a stabilizer measurement provided by the code. The methodology provides for assigning each of the different edges in the graph to a select one of “G” number of different edge types and performing at least G-number of temporally-separated rounds of qubit operations that each enact concurrent multi-qubit operations on endpoints of a subset of the edges assigned to a same one of the G different edge types.

Abstract: A quantum measurement circuit implements a hypergraph product code (HPG). A syndrome can be extracted from the circuit by preparing a readout qubit of the quantum measurement circuit in a known state, preparing a row-based measurement gadget, and preparing a column-based measurement gadget in the quantum measurement circuit. The row-based measurement gadget entangles the readout qubit with a first subset of the target set of data qubits in a same row of the quantum measurement circuit as the readout qubit, and the column based gadget entangles the readout qubit with a second subset of the target set of data qubits in a same column of the quantum measurement circuit as the readout qubit. The syndrome is extracted by measuring the readout qubit to extract the parity of the target set of data qubits.

Abstract: A disclosed methodology for syndrome extraction in a quantum measurement circuit includes generating a graph representing a code implemented by the quantum measurement circuit. The graph includes bit nodes corresponding to data qubits in the quantum measurement circuit, check nodes corresponding to syndrome qubits in the quantum measurement circuit, and edges between the bit nodes and check nodes that are each associated with a stabilizer measurement provided by the code. The methodology provides for assigning each of the different edges in the graph to a select one of “G” number of different edge types and performing at least G-number of temporally-separated rounds of qubit operations that each enact concurrent multi-qubit operations on endpoints of a subset of the edges assigned to a same one of the G different edge types.

Abstract: A sensing apparatus for monitoring a substance contained in a storage building, the apparatus comprising: a mounting bracket configured to be secured to a roof of the storage building; a sensing assembly mounted to the mounting bracket, the sensing assembly including: a sensor for measuring a parameter of the substance in the storage building when the sensor is in a measuring orientation; and a housing for housing the sensor, the housing being pivotably connected to the mounting bracket and being freely pivotable relative to the mounting bracket about a pivot axis, the housing being orientable in an operative position in which the sensor is in the measuring orientation to allow the sensor to measure the parameter of the substance, the sensing assembly having a center of mass located below the pivot axis such that the housing is urged towards the operative orientation by gravity.

Abstract: A sensing apparatus for monitoring a substance contained in a storage building the apparatus comprising: a mounting bracket configured to be secured to a roof of the storage building; a sensing assembly mounted to the mounting bracket, the sensing assembly including: a sensor for measuring a parameter of the substance in the storage building when the sensor is in a measuring orientation; and a housing for housing the sensor, the housing being pivotably connected to the mounting bracket and being freely pivotable relative to the mounting bracket about a pivot axis, the housing being orientable in an operative position in which the sensor is in the measuring orientation to allow the sensor to measure the parameter of the substance, the sensing assembly having a center of mass located below the pivot axis such that the housing is urged towards the operative orientation by gravity.

Abstract: It is described a Clostridium difficile (C-difficile) toxins A and/or B as a target for therapy, including passive immunotherapy, and particularly prevention of C-difficile intoxication in human or other animals. It is also described a polypeptide comprising a portion of C-difficile toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody. It is also disclosed a method for generating a neutralizing antibody directed against C-difficile toxins A and/or B. It is also provided a novel formulation that combines key toxins A and/or B epitope antibodies, located in three key domains of toxins A and/or B, for neutralisation of the toxins A and/or B, at any stage of toxins A and/or B intoxication related to C-difficile infection. The novel formulation of toxins A and/or B epitope antibodies are useful in immunotherapy, for therapeutic and/or prophylactic mediation of C-difficile intoxication.

Abstract: It is described a Clostridium difficile (C-difficile) toxins A and/or B as a target for therapy, including passive immunotherapy, and particularly prevention of C-difficile intoxication in human or other animals. It is also described a polypeptide comprising a portion of C-difficile toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody. It is also disclosed a method for generating a neutralizing antibody directed against C-difficile toxins A and/or B. It is also provided a novel formulation that combines key toxins A and/or B epitope antibodies, located in three key domains of toxins A and/or B, for neutralizing toxins A and/or B, at any stage of toxins A and/or B intoxication related to C-difficile infection. The novel formulation of toxins A and/or B epitope antibodies are useful in immunotherapy, for therapeutic and/or prophylactic mediation of C-difficile intoxication.

Abstract: It is described a Clostridium difficile (C-difficile) toxins A and/or B as a target for therapy, including passive immunotherapy, and particularly prevention of C-difficile intoxication in human or other animals. It is also described a polypeptide comprising a portion of C-difficile toxins A and/or B sequence being an epitope for anti-toxins A and/or B antibody. It disclosed a method for generating a neutralizing antibody directed against C-difficile toxins A and/or B. It is also provided a novel formulation that combines key toxins A and/or B epitope antibodies, located in three key domains of toxins A and/or B, for neutralisation of the toxins A and/or B, at any stage of toxins A and/or B intoxication related to C-difficile infection. The novel formulation of toxins A and/or B epitope antibodies are useful in immunotherapy, for 10 therapeutic and/or prophylactic mediation of C-difficile intoxication.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, R5, and G are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: The present invention relates to compounds of formula (I) [Chemical formula should be inserted here. Please see paper copy] as well as pharmaceutically acceptable salts and pharmaceutical compositions including the compounds are prepared or thereof: wherein, A1, A2, R1, R2, R3, R4, and R5 and n are as defined in the specification. The compounds of formula (I) are useful in therapy.

Abstract: Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, R5, and G are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: The present invention relates to a process of preparing a compound of formula II, wherein R1, n, m and p are defined in the specification.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, n and A are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: Compounds of Formulae (IA), (IB) or pharmaceutically acceptable salts thereof; wherein Het, X1, R1, R2, R3, R3a and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3, R4, n and Ar are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, R5, and G are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.